Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
November 16 2021 - 7:00AM
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company
developing life-changing treatments and next-generation
adeno-associated virus (AAV) platform technologies, today announced
it will present preclinical data from its vectorized antibody
program at the 26th Society for Neuro-Oncology (SNO) Annual Meeting
on Nov. 19, 2021.
SNO Oral Presentation Details: Title: AAV
mediated brain delivery of an ADCC-enhanced antibody obviates
xenograft growth in mouse models of HER2+ breast cancer brain
metastasisAbstract Number: EXTH-02Abstract Session: CNS
MetastasesPresenter: Dan R. Laks, Ph.D., Scientist II, Voyager
TherapeuticsPresentation Time: 4:15 p.m. ET
About Voyager TherapeuticsVoyager Therapeutics
(Nasdaq: VYGR) is leading the next generation of AAV gene therapy
to unlock the potential of the technology to treat devastating
diseases. Proprietary capsids born from the Company’s TRACERTM
screening platform are powering a rich early-stage pipeline of new
and second-generation programs and may elevate the field to
overcome the limitations of conventional gene therapy vectors
across neurologic disorders and other therapeutic areas.
voyagertherapeutics.com
LinkedIn Twitter
Voyager Contacts
Investors
Investors@voyagertherapeutics.com
Media
Scott Santiamo
ssantiamo@vygr.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Apr 2023 to Apr 2024